SCHEMBL4456250

SCHEMBL4456250

C[C@H]1CC[C@@H](N)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL433619 1.00
SCHEMBL49052 1.00
Hydrochloric Acid SCHEMBL1334305 0.96
Ammonia Solution, Strong SCHEMBL20530704 0.96
Hydrochloric Acid SCHEMBL1076485 0.96
Hydrochloric Acid SCHEMBL1241497 0.96
Methyl Alcohol SCHEMBL11519103 0.93 ESR2 (0.32)
Methyl Alcohol SCHEMBL11189585 0.93 ESR2 (0.32)
SCHEMBL16248242 0.90
SCHEMBL5968011 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109824520-B Preparation method of cis-4-methylcyclohexylamine 苏州海犇药业有限公司 2021-07-23 CN claimed
CN-115835909-B Cannabinoid receptor type 2 (CB 2) modulators and uses thereof 泰昂治疗公司 2026-05-15 CN disclosed
EP-4733293-A1 METHOD FOR PRODUCING ALKYL FLUORIDE COMPOUND, AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALKYL FLUORIDE COMPOUND Mitsubishi Materials Electronic Chemicals Co., Ltd. (JP) 2026-04-29 EP disclosed
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
WO-2024262208-A1 METHOD FOR PRODUCING ALKYL FLUORIDE COMPOUND, AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALKYL FLUORIDE COMPOUND 三菱マテリアル電子化成株式会社 2024-12-26 WO disclosed
US-12084400-B2 Trisamide compounds and compositions comprising the same MILLIKEN & COMPANY (US) 2024-09-10 US disclosed
US-20240252504-A1 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF TEON THERAPEUTICS INC (US) 2024-08-01 US disclosed
US-11957689-B2 Cannabinoid receptor type 2 (CB2) modulators and uses thereof TEON THERAPEUTICS, INC. (US) 2024-04-16 US disclosed
US-20240025842-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & COMPANY 2024-01-25 US disclosed
US-11813267-B2 DNA-PK inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-11-14 US disclosed
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 US disclosed
EP-1534681-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-06-01 EP disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 US disclosed
WO-2004002960-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-01-08 WO disclosed
EP-0780340-B1 Intercalates and exfoliates formed with functional monomeric organic compounds; composite materials containing same and methods of modifying rheology therewith AMCOL INTERNATIONAL CORP (US) 2002-03-20 EP disclosed
EP-0780340-A1 Intercalates and exfoliates formed with functional monomeric organic compounds; composite materials containing same and methods of modifying rheology therewith AMCOL INTERNATIONAL CORPORATION (US) 1997-06-25 EP disclosed
EP-0535250-B1 NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE TSUMURA & CO (JP) 1996-06-19 EP disclosed
EP-0705817-A1 New cannamide derivatives and their use as allergy inhibitors TSUMURA &amp; CO. (JP) 1996-04-10 EP disclosed
US-5344845-A Methyl 4(4-acetoxy-3-methoxycinnamanide and salts as an immunosuppressive drug for allergic reactions TSUMURA & CO. (JP) 1994-09-06 US disclosed
EP-0535250-A1 NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE TSUMURA &amp; CO. (JP) 1993-04-07 EP disclosed